Several brokerages have updated their recommendations and price targets on shares of Arbutus Biopharma Corporation (NASDAQ: ABUS) in the last few weeks:

  • 11/7/2017 – Arbutus Biopharma Corporation was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/7/2017 – Arbutus Biopharma Corporation had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $5.00 price target on the stock, up previously from $4.00.
  • 11/7/2017 – Arbutus Biopharma Corporation was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. “
  • 10/25/2017 – Arbutus Biopharma Corporation was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 10/4/2017 – Arbutus Biopharma Corporation had its “outperform” rating reaffirmed by analysts at JMP Securities. They now have a $13.00 price target on the stock, up previously from $12.00.
  • 9/21/2017 – Arbutus Biopharma Corporation was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 9/20/2017 – Arbutus Biopharma Corporation had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.

Arbutus Biopharma Corporation (ABUS) opened at $5.90 on Tuesday. Arbutus Biopharma Corporation has a 12 month low of $2.35 and a 12 month high of $8.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03.

In other news, insider Michael J. Sofia sold 10,000 shares of the stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is currently owned by company insiders.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Receive News & Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.